200-125, it exam questions and answers 300-075, 100-105, 300-101, 210-260, exam study guide 300-115, 200-310, 300-135, 300-320, 210-060, 300-070, 200-105, it certification exam 210-065, 1Z0-144, exam certificate MB2-712, 1V0-601, 640-916, 500-007, best exam dumps 200-601, 642-980, sure to pass exam 700-037, H12-224, 70-469, it exam online study PEGACSA71V1, 210-060, testing online 700-001, HP0-M101, 070-483, success pass exam 210-065, EX200, PCNSE7, 070-331, 101-400, latest exam pdf 98-365, 70-494, hotest exam ISSMP, HP0-Y50, 70-462, S90-04A, exam material 250-315, ADM-201, CISSP-ISSMP, remark for it exam 300-465, 648-232, GMAT-QUANTITIVE, MB5-705, E20-324, base on latest exam testing 70-981, 70-466, IREB, 1Z0-584, 810-403, perfect exam certification 642-997, M5050-793, AX0-100, 2V0-641, 300-375, NSE7, professional exam study 2V0-621, 1Y0-253, 070-332, C2040-985, VCS-411, to study to pass 102-400, 350-018, MB6-702, CSTE, get the exam certification 500-260, 300-365, study latest exam 70-331, 300-135, 642-035, 642-889, 210-260, CGEIT, exam study dump GMAT-VERBAL, 2V0-621D, 301B, 70-246, 250-318, latest updated exam 1Z0-062, 1Z0-898, 352-001, C2090-620, SY0-401, 70-346, 400-101, 1D0-635, A00-281, exam study online 1Z0-882, 1Z0-599, C2090-560, 010-151, M70-201, 070-488, 70-489, it certification material A2040-409, 8002, 200-355, 70-247, CAT-140, TB0-103, how to get the exam certificate high-speed 74-343, 70-347, 4A0-100, C2090-611, 7 Years experience 650-195, 640-911, ensure to help student 1Z0-520, HP3-F18, PMP, 200-310, 100% Safe shopping experience 070-417, 1Z0-333, 300-070, CISA, 300-206, There is a same question come twice and there is different answers for both. MB3-861, CWNA-106, Not take the exam yet. Find few incorrect answers in dump. “Relevant Team” helps with that. I am writing my exam on coming Saturday. Hope I will pass. 1Z0-482, EX300, Passed in France successfully ! Thanks 70-498, 220-901, 500-205, 1Z0-058, 1Z0-803, 700-501, This Dump is 100% valid, Pass today. Dump valid. LFCS, 300-115, 70-412, One Year Free Update 070-243, MB0-001, 300-085, 6000+ Products Instant Download 210-451, HP2-N48, 70-486, 70-533, 20+ Representatives Providing 24/7 Support 1Z0-591, 70-980, 300-209, 200-120, 642-584, P2090-095, I pass this morning with 965 points. Thanks for your hard work. VCP550, 70-385, P2090-054, 3I0-012, 365 days Free Update 070-489, 98-364, 70-417, 98-349, 1Z0-102, 3 days of preparation before your test 642-999, 3304, GCIH, ICGB, CAP, 300-208, Passed in France successfully ! Thanks 1Z0-151, TB0-123, 3309, CAS-002, Valid Dump. Exam is all multiple-choice. 300-320, 400-201, MB3-859, 700-505, 1Z0-533, This dumps is valid for the actual exam.. 77-884, 98-361, am a first timer . and fear to sit for the exam.. thanks for helping me pass. VCP550D, JN0-332, 640-792, C9510-317, 070-462, I’m going to take my exam the next month. I hope I can pass easily. 600-455, 642-996, C2010-595, 500-254, 648-238, We provide you 100% money back guarantee C2010-570, 200-105, 646-580, 70-412, | 74-343, | 070-417, | M70-201, | MB2-708, | HP0-J73, | 1Z0-034, | 1Z0-522, | PRINCE2-Practitioner, | 1V0-605, | 2V0-621, | E20-593, | 640-722, | 70-461, | HP0-Y47, | AX0-100, |

THE BIG PICTURE

The UK government commissioned report published in 2016 by Jim O’Neill, highlights the growing problem of antimicrobial resistance (AMR). This is particularly evident for Gram negative bacteria, where resistance is now emerging to even last resort antibiotics, such as colistin. The report suggests that unless action is taken, the global burden of deaths from AMR could balloon to 10 million lives each year by 2050. 

Phico Therapeutics is pioneering a radical approach to antibacterial therapy which it believes could form the basis of a solution. By targeting and inactivating the bacterial DNA directly, irrespective of its sequence, mutations in the bacterial DNA don’t prevent SASP from working. Phico’s SASPject products can directly tackle the genetic cause of antibiotic resistance.

THE COMPANY

Phico Therapeutics is a biotechnology company developing a novel platform technology which it believes could form the basis for a new generation of antibiotics to overcome antibacterial resistance.

The company, founded in Cambridge by Dr Heather Fairhead, is built around the SASPject™ platform, which utilises a unique anti-bacterial protein, SASP, which targets and deactivates bacterial DNA stopping bacteria from metabolising or reproducing. Phico has raised over £22 M from business angels, venture investment, high net-worth individuals, the Wellcome Trust and Government grants. Phico’s goal is to advance the science of antibacterial therapy to help overcome the problem of bacterial resistance.

TECHNOLOGY

Our SASPject™ platform delivers pan-spectrum anti-bacterial proteins called small acid-soluble spore proteins, or SASPs, to selected bacterial species using targetable nano-delivery vehicles (NDVs). SASPject™ works by injecting a gene that encodes SASP directly into the targeted bacteria. The injected gene then produces SASPs, which bind to bacterial DNA and inactivate it. SASPs “turn off” DNA so the targeted bacterial cell cannot metabolise or reproduce. The immune system can then remove the bacteria from the body.

SASPs bind to all bacterial DNA, irrespective of the sequence of that DNA. Spontaneous mutations in DNA, or the import of new DNA that gives new characteristics to the bacterial cell, are key ways in which bacteria develop resistance to antibiotics. Neither of these strategies affects the ability of SASP to bind to and inactivate bacterial DNA.

This approach has the potential to provide a number of significant advantages over traditional antibiotics:

  • The unique mode of action of SASP makes it unlikely the bacteria will be able to develop resistance to this anti-bacterial protein
  • SASPject technology can be used to target any selected bacteria, individual or multiple bacterial species or genera, including those that are multi-antibiotic resistant.
  • Unlike conventional antibiotics, SASPject has no effect on any bacteria other than those at which it is targeted. Normal skin and gut bacteria (“good bacteria”) are unharmed.
  • SASPject target specificity prevents the release of toxins and other inflammatory cell components from non-target bacteria thus potentially minimising associated side effects.
  • SASPject has the potential to limit the further spread of antibiotic resistance genes and to shrink the current antibiotic resistance pool

PRODUCTS

SASPject™ PT3


SASPject™ PT3 is being developed against  Pseudomonas aeruginosa. These infections can involve any part of the human body, but most commonly cause urinary tract, lung, bloodstream, wound/burn, and intra-abdominal infections. P. aeruginosa is responsible for a number of hospital-acquired infections with its incidence in intensive care units having risen sharply and its incidence almost doubling between the mid 1970’s and early 2000’s. The increasing incidence of P. aeruginosa of strains showing multi-drug resistance against commonly used first-line antibiotics has resulted in the U.S. CDC (Centers for Disease Control and Prevention) classifying P. aeruginosa as a serious threat to human health. The PT3 project has been supported by Innovate UK.

SASPject™ PT4 and PT5


SASPject™ PT4 and SASPject™ PT5 are being developed for systemic (intravenous) use against both Klebsiella pneumoniae and Escherichia coli  respectively. These bacteria cause a wide range of infections, which can be serious or life threatening as isolates which are resistant to almost all conventional antibiotics continue to spread around the globe, resulting in very poor treatment outcomes. PT4 and PT5 projects are supported by a Wellcome Translation Award.

SASPject™ PT1.2


SASPject™ PT1.2 targets Staphylococcus aureus, including MRSA. MRSA infections are now a global problem in hospitals, with thousands of fatalities recorded as a result of their presence, and their control is vital to many national health systems. SASPject™ PT1.2 will be used for the intra-nasal decolonisation of the bacteria. A Phase I clinical trial has been successfully completed.

TEAM

Heather-Fairhead

Dr Heather Fairhead

FOUNDER AND CEO

Dr Fairhead has over 17 years’ experience directing research teams in a variety of disciplines and has led Phico in developing SASPject technology from a concept through a Phase I clinical trial.  Prior to her scientific career, Heather worked for 10 years in sales and marketing in a wide range of industries.

Tony Martin
Dr Anthony MartinCHAIRMAN

Dr Martin has more than 25 years' experience in providing life science and biotechnology companies counsel on a range of strategic, management and funding issues, including as Chairman of anti-infectives company, NeuTec Pharma plc, where he played a pivotal role in guiding the company’s sale to Novartis for over £300M.

Bob Nolan 2
Dr Robert NolanNON-EXECUTIVE DIRECTOR

Robert has over 30 years’ experience in big pharma, including from 1989 to end 2004 as Director of Global Licensing at AstraZeneca. Bob is a non-executive director of Epistem Ltd. He gained his Ph.D. in biochemistry from King’s College, London, and completed two post-doctoral fellowships in the US at Dartmouth Medical School and MIT.

Allan Hirst
Allan HirstNON-EXECUTIVE DIRECTOR

Allan spent 24 years with Citigroup, in the last 15 years leading Citibank’s expansion into Central and Eastern Europe, Russia and Central Asia. Allan sits on the Board of the Financial Services Volunteer Corp and will shortly be joining the Board of the Georgia Healthcare Group.

Lucy Block
Lucy BlockNON-EXECUTIVE DIRECTOR, COMPANY SECRETARY

Lucy has almost 20 years’ experience providing business strategy, business development and financing support to a number of start-up and early stage biotechnology companies.

Thompsonweb
DR NICKI THOMPSONCHIEF BUSINESS OFFICER

Over 25 years experience in Pharma and Biotech R&D. VP & Global Head, External Drug Discovery, Roche; Senior Director Business Development, GSK; Drug Discovery Head, Syntaxin; Allergic Mechanisms Head, GSK

Jamesweb1
DR JAMES CASSRESEARCH MANAGER

Microbiologist with over 10 years’ experience in the Biotech and anti-infectives industy; Biocontrol Ltd (Ampliphi Biosciences)

MEDIA AND INVESTORS

MEDIA


17/11/2016

BBC Radio Cambridgeshire - Morning Show: Dr Heather Fairhead, Phico's CEO, talks to Dotty McLeod about PT3

15/11/2016

Press Release: Phico moves forward with global fight against antibiotic resistant ‘superbugs’, raising more than £3.5M to take its lead PT3 program into the clinic.

26/01/2016

Press Release: Phico Appoints Dr Nicki Thompson as CBO

18/11/2015

BBC Radio Cambridgeshire. Dr Heather Fairhead, Phico's CEO, talks to Dotty McLeod on the Breaksfast Show during World Antibiotic Awareness Week 2015.

18/11/2015

BBC Look East. Dr Heather Fairhead, Phico's CEO, is interviewed as part of an article on antibiotic resistance, during the 2015 World Antibiotic Awareness Week.

03/09/2015

Press Release: Phico Therapeutics Receives Translation Award To Advance Its SASPject™ PT4 aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials

08/01/2015

The Guardian: Scientist raises £750,000 to develop weapon against MRSA

08/01/2015

Andie Harper's Mid Morning Show, BBC Radio Cambridgeshire: Radio Interview with Phico Therapeutics' CEO, Dr Heather Fairhead. Heather discusses the problems we are facing with antibiotic resistant bacteria.

03/11/2013

BBC Radio 5 Live: Interview with Dr Heather Fairhead, Phico's CEO, following the call to arms for development of new antibiotics by Professor Dame Sally Davies, UK Chief Medical Officer.

06/01/2013

Cambridge Business: Article on Dr Heather Fairhead, Phico's CEO.

11/01/2014

Wired Magazine: Phico Therapeutics and its technology features in the pages of Wired Magazine.

TWITTER FEED


A new assay directly identifies individual small bacterial DNA molecules and antibiotic resistance genes they encode
https://t.co/yfSyaVzDFf
Results of the European Survey on Carbapenamase-Producing Enterobacteriaceae funded by the ECDC have been published https://t.co/rLpkLGwHoB
A new study demands more detailed and reliable surveillance data to improve measures against #AntibioticResistance https://t.co/a5vl1KdPep

CONTACTS

If you are interested in learning more about what we do, or have general enquiries:

+44(0)1223 496755

info@phicotx.co.uk

Phico Therapeutics Ltd, Babraham Research Campus, Babraham, Cambridge, CB22 3AT.

#phicotx

www.linkedin.com/company/phico-therapeutics-ltd

For media enquiries please contact:

Consilium Strategic Communications

Mary-Jane Elliott: +44(0)203 709 5702

Jessica Hodgson: +44(0)203 709 5703

hodgson@consilium-comms.com

CAREERS

If you are interested in a career with Phico Therapeutics, please send your CV and a covering letter to:

Susan Hatley

phico.admin@phicotx.co.uk referencing the appropriate job in the subject line.